Dataset Information

Association between MIR499A rs3746444 polymorphism and breast cancer susceptibility: a meta-analysis.

ABSTRACT: Numerous studies have investigated the association of MIR499A rs3746444 polymorphism with breast cancer susceptibility, but the results have been inconsistent. In this work, we performed a meta-analysis to obtain a more reliable estimate of the association between the polymorphism and susceptibility to breast cancer. A comprehensive literature search was conducted on PubMed, Scopus, Web of Science (WoS), China National Knowledge Infrastructure (CNKI), VIP and Wanfang databases up to January 2020. A total of 14 studies involving 6,797 cases and 8,534 controls were included for analysis under five genetic models: homozygous (GG vs. AA), heterozygous (AG vs. AA), dominant (AG?+?GG vs. AA), recessive (GG vs. AA?+?AG) and allele (G vs. A). A statistically significant association was observed between the polymorphism and an increased breast cancer susceptibility under all genetic models (homozygous, OR?=?1.33, 95% CI?=?1.03-1.71, P?=?0.03; heterozygous, OR?=?1.08, 95% CI?=?1.00-1.16, P?=?0.04; dominant, OR?=?1.15, 95% CI?=?1.02-1.30; P?=?0.03; recessive, OR?=?1.35, 95% CI?=?1.06-1.72, P?=?0.01; allele, OR?=?1.12, 95% CI?=?1.00-1.26, P?=?0.04). Subgroup analysis based on ethnicity suggested that significant association was present only among Asians, but not Caucasians. In conclusion, MIR499A rs3746444 polymorphism was significantly associated with breast cancer susceptibility among Asians, suggesting its potential use as a genetic risk marker in this population.

SUBMITTER: Tan SC

PROVIDER: S-EPMC7044335 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Association between MIR499A rs3746444 polymorphism and breast cancer susceptibility: a meta-analysis.

Tan Shing Cheng SC Lim Poh Ying PY Fang Jie J Mokhtar Mira Farzana Mohamad MFM Hanif Ezanee Azlina Mohamad EAM Jamal Rahman R

Scientific reports 20200226 1

Numerous studies have investigated the association of MIR499A rs3746444 polymorphism with breast cancer susceptibility, but the results have been inconsistent. In this work, we performed a meta-analysis to obtain a more reliable estimate of the association between the polymorphism and susceptibility to breast cancer. A comprehensive literature search was conducted on PubMed, Scopus, Web of Science (WoS), China National Knowledge Infrastructure (CNKI), VIP and Wanfang databases up to January 2020 ...[more]

PMID: 32103099

Similar Datasets

Project description:Estrogen has played an important role in the development of breast cancer. ER-? PvuII gene polymorphism is in close association with the occurrence risk of breast cancer, but no consensus has been achieved currently.PubMed, Embase, China National Knowledge Infrastructure (CNKI) database, Wanfang database, and VIP database were retrieved to collect the case-control studies on association between ER? gene Pvu II polymorphism and breast cancer risk published before September 1, 2017. Newcastle-Ottawa Scale (NOS) was used to assess the quality of the literatures, Stata 14.0 software was applied for meta-analysis, and the pooled odds ratio (OR) and 95% confidence interval (95% CI) were calculated. The subgroup analysis was performed to assess the confounding factors, followed by assessment of publication bias and sensitivity analysis.A total of 26 studies were enrolled in the analysis based on inclusion criteria, which included 15,360 patients and 26,423 controls. The results demonstrated that ER? gene Pvu II polymorphism was in significant association with the decrease of breast cancer risk in 3 genetic models (C vs T, OR?=?0.962, 95% CI?=?0.933-0.992, P?=?.012; CC vs TT, OR?=?0.911, 95% CI?=?0.856-0.969, P?=?.003; CC vs TT/CT, OR?=?0.923, 95% CI?=?0.874-0.975, P?=?.004). Subgroup analysis was conducted on the basis of ethnicity and source of controls, whose results illustrated that ER? gene Pvu II polymorphism was in significant association with the decrease of breast cancer risk in Asians rather than in Caucasians (CC vs TT, OR?=?0.862, 95% CI?=?0.750-0.922, P?=?.038; CC vs TT/CT, OR?=?0.851, 95% CI?=?0.755-0.959, P?=?.008). In population-based subgroup rather than in hospital-based subgroup, ER? gene Pvu II polymorphism was in significant association with the decrease of breast cancer risk in the allele model, homozygous model, dominant model, and recessive model (C vs T, OR?=?0.943, 95% CI?=?0.911-0.977, P?=?.001; CC vs TT, OR?=?0.878, 95% CI?=?0.817-0.944, P?=?.000; CC/CT vs TT, OR?=?0.936, 95% CI?=?0.881-0.994, P?=?.031; CC vs TT/CT, OR?=?0.902, 95% CI?=?0.847-0.960, P?=?.001).ER? gene Pvu II polymorphism exerts an important function in the progression of breast cancer.

Project description:Research on the polymorphism of breast cancer (BC) helps to search the BC susceptibility gene for mass screening, early diagnosis, and gene therapy, which has become a hotspot in BC research field. Previous studies have suggested associations between rs11200014, rs2981579, and rs1219648 polymorphisms and cancer risk. The aim of this study was to evaluate the relationship between rs11200014, rs2981579, and rs1219648 polymorphism and BC risk.PubMed, Web of science, and the Cochrane Library databases were searched before October 11, 2015, to identify relevant studies. Odds ratios (ORs) and 95% confidence intervals (CIs) were used to estimate the strength of associations. Sensitivity and subgroup analyses were conducted. All included cases should have been diagnosed by a pathological examination.Twenty-six studies published from 2007 to 2015 were included in this meta-analysis. The pooled results showed that there was a significant association between all the 3 variants and BC risk in any genetic model. When stratified by Source of controls, the results showed the same association between rs2981579 polymorphism and BC susceptibility in hospital-based (HB) group, although there was not any genetic model attained statistical correlation in population-based (PB) group. Subgroup analysis was performed on rs1219648 by ethnicity and Source of controls, and the effects remained in Asians, Caucasians, HB, and PB groups.This meta-analysis of case-control studies provides strong evidence that fibroblast growth factor 2 (FGFR2; rs11200014, rs2981579, and rs1219648) polymorphisms are significantly associated with the BC risk. For rs2981579, the association remained in hospital populations, while not in general populations. For rs1219648, the association remained in Asians, Caucasians, hospital populations, and general populations. However, further large-scale multicenter epidemiological studies are warranted to confirm this finding and the molecular mechanism for the associations need to be elucidated in future studies.

Dataset Information

Association between MIR499A rs3746444 polymorphism and breast cancer susceptibility: a meta-analysis.

Publications

Association between MIR499A rs3746444 polymorphism and breast cancer susceptibility: a meta-analysis.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure